Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Risk factors for mortality in patients with mucormycosis.

Spellberg B, Kontoyiannis DP, Fredricks D, Morris MI, Perfect JR, Chin-Hong PV, Ibrahim AS, Brass EP.

Med Mycol. 2012 Aug;50(6):611-8. doi: 10.3109/13693786.2012.669502. Epub 2012 Mar 21.

2.

The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial.

Spellberg B, Ibrahim AS, Chin-Hong PV, Kontoyiannis DP, Morris MI, Perfect JR, Fredricks D, Brass EP.

J Antimicrob Chemother. 2012 Mar;67(3):715-22. doi: 10.1093/jac/dkr375. Epub 2011 Sep 20.

3.

The iron chelator deferasirox protects mice from mucormycosis through iron starvation.

Ibrahim AS, Gebermariam T, Fu Y, Lin L, Husseiny MI, French SW, Schwartz J, Skory CD, Edwards JE Jr, Spellberg BJ.

J Clin Invest. 2007 Sep;117(9):2649-57.

4.

Deferasirox as adjunctive therapy for mucormycosis.

Donnelly JP, Lahav M.

J Antimicrob Chemother. 2012 Mar;67(3):519-20. doi: 10.1093/jac/dkr540. Epub 2011 Dec 20.

PMID:
22186877
5.

Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis.

Reed C, Ibrahim A, Edwards JE Jr, Walot I, Spellberg B.

Antimicrob Agents Chemother. 2006 Nov;50(11):3968-9. Epub 2006 Sep 25. No abstract available.

6.

Recent advances in the management of mucormycosis: from bench to bedside.

Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards J Jr, Ibrahim AS.

Clin Infect Dis. 2009 Jun 15;48(12):1743-51. doi: 10.1086/599105. Review.

7.

Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment.

Ibrahim AS, Spellberg B, Edwards J Jr.

Curr Opin Infect Dis. 2008 Dec;21(6):620-5. doi: 10.1097/QCO.0b013e3283165fd1. Review.

8.

Prospective antifungal therapy (PATH) alliance(®) : focus on mucormycosis.

Kontoyiannis DP, Azie N, Franks B, Horn DL.

Mycoses. 2014 Apr;57(4):240-6. doi: 10.1111/myc.12149. Epub 2013 Oct 22.

PMID:
24147728
9.

Mucormycosis in hematologic malignancies: an emerging fungal infection.

Nosari A, Oreste P, Montillo M, Carrafiello G, Draisci M, Muti G, Molteni A, Morra E.

Haematologica. 2000 Oct;85(10):1068-71.

10.

Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis.

Spellberg B, Andes D, Perez M, Anglim A, Bonilla H, Mathisen GE, Walsh TJ, Ibrahim AS.

Antimicrob Agents Chemother. 2009 Jul;53(7):3122-5. doi: 10.1128/AAC.00361-09. Epub 2009 May 11.

11.

Focus on invasive mucormycosis in paediatric haematology oncology patients: a series of 11 cases.

Phulpin-Weibel A, Rivier A, Leblanc T, Bertrand Y, Chastagner P.

Mycoses. 2013 May;56(3):236-40. doi: 10.1111/myc.12010. Epub 2012 Oct 1.

PMID:
23020159
12.

Mortality in hematologic malignancy and hematopoietic stem cell transplant patients with mucormycosis, 2001 to 2009.

Hammond SP, Baden LR, Marty FM.

Antimicrob Agents Chemother. 2011 Nov;55(11):5018-21. doi: 10.1128/AAC.00536-11. Epub 2011 Aug 29.

13.

Successful nonoperative management of gastrointestinal mucormycosis: novel therapy for invasive disease.

Mezhir JJ, Mullane KM, Zarling J, Satoskar R, Pai RK, Roggin KK.

Surg Infect (Larchmt). 2009 Oct;10(5):447-51. doi: 10.1089/sur.2008.049. Review.

PMID:
19485785
14.

Mucormycosis in hematologic patients.

Pagano L, Offidani M, Fianchi L, Nosari A, Candoni A, Picardi M, Corvatta L, D'Antonio D, Girmenia C, Martino P, Del Favero A; GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Infection Program.

Haematologica. 2004 Feb;89(2):207-14. Review.

15.

[Pulmonary mucormycosis: report of 5 cases and review of 46 cases reported in China].

Yang YM, Fang BM, Xu XM, Fang F, Pan MM, Zhong XF, Sun TY.

Zhonghua Jie He He Hu Xi Za Zhi. 2013 Aug;36(8):572-6. Chinese.

PMID:
24252732
16.

Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis.

Reed C, Bryant R, Ibrahim AS, Edwards J Jr, Filler SG, Goldberg R, Spellberg B.

Clin Infect Dis. 2008 Aug 1;47(3):364-71. doi: 10.1086/589857.

17.

Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis.

Lewis RE, Albert ND, Liao G, Hou J, Prince RA, Kontoyiannis DP.

Antimicrob Agents Chemother. 2010 Mar;54(3):1298-304. doi: 10.1128/AAC.01222-09. Epub 2009 Dec 28.

18.
19.

Stability in the cumulative incidence, severity and mortality of 101 cases of invasive mucormycosis in high-risk patients from 1995 to 2011: a comparison of eras immediately before and after the availability of voriconazole and echinocandin-amphotericin combination therapies.

Abidi MZ, Sohail MR, Cummins N, Wilhelm M, Wengenack N, Brumble L, Shah H, Jane Hata D, McCullough A, Wendel A, Vikram HR, Kusne S, Litzow M, Letendre L, Lahr BD, Poeschla E, Walker RC.

Mycoses. 2014 Nov;57(11):687-98. doi: 10.1111/myc.12222. Epub 2014 Jul 18.

20.

Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis.

Lewis RE, Albert ND, Kontoyiannis DP.

Antimicrob Agents Chemother. 2014 Nov;58(11):6767-72. doi: 10.1128/AAC.03569-14. Epub 2014 Sep 2.

Supplemental Content

Support Center